Literature DB >> 14684850

The EZC-prostate model: noninvasive prostate imaging in living mice.

Xiaoming Xie1, Zheng Luo, Kevin M Slawin, David M Spencer.   

Abstract

Recently, progress in the development of prostate-specific promoters and high resolution imaging techniques has made real-time monitoring of transgenic expression possible, opening a vista of potentially important in vivo models of prostate disease. Herein, we describe a novel prostate reporter model, called the EZC-prostate model that permits both ex vivo and in vivo imaging of the prostate using a sensitive charge-coupled device. Firefly luciferase and enhanced green fluorescent protein were targeted to the prostate epithelium using the composite human kallikrein 2 (hK2)-based promoter, hK2-E3/P. In EZC-prostate mice, the ventral and dorsal/lateral prostate lobes were brilliant green under fluorescence microscopy, with expression localized to the secretory epithelium. In contrast, enhanced green fluorescent protein was undetectable in the anterior lobes of prostate, seminal vesicles, testes, liver, lung, and brain. The kinetics of luciferase activity in intact and castrated living mice monitored with the IVIS charge-coupled device-based imaging system confirmed that firefly luciferase expression was largely prostate restricted, increased with age up to 24 wk, and was androgen dependent. Decreases in reporter expression after 24 wk may reflect well known, age-related decreases in androgen signaling with age in humans. Ex vivo imaging of microdissected animals further confirmed that the luminescence detected in living mice emanated predominately from the prostate, with minor signals originating from the testes and cecum. These data demonstrate that the hK2-E3/P promoter directs strong prostate-specific expression in a transgenic mouse model. Multigenic models, generated by crosses with various hyperplastic and neoplastic prostate disease models, could potentially provide powerful new tools in longitudinal monitoring of changes in prostate size, androgen signaling, metastases, or response to novel therapies without sacrificing large cohorts of animals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684850     DOI: 10.1210/me.2003-0316

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  7 in total

1.  AEG-1 promoter-mediated imaging of prostate cancer.

Authors:  Akrita Bhatnagar; Yuchuan Wang; Ronnie C Mease; Matthew Gabrielson; Polina Sysa; Il Minn; Gilbert Green; Brian Simmons; Kathleen Gabrielson; Siddik Sarkar; Paul B Fisher; Martin G Pomper
Journal:  Cancer Res       Date:  2014-08-21       Impact factor: 12.701

Review 2.  Cancer imaging: Gene transcription-based imaging and therapeutic systems.

Authors:  Hyo-eun C Bhang; Martin G Pomper
Journal:  Int J Biochem Cell Biol       Date:  2012-02-10       Impact factor: 5.085

3.  Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy.

Authors:  M Iyer; F B Salazar; X Lewis; L Zhang; L Wu; M Carey; S S Gambhir
Journal:  Transgenic Res       Date:  2005-02       Impact factor: 2.788

4.  Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.

Authors:  Xiaoming Xie; Yanan Kong; Hailin Tang; Lu Yang; Jennifer L Hsu; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2014-04-30       Impact factor: 6.261

5.  Rapid ex vivo imaging of PAIII prostate to bone tumor with SWIFT-MRI.

Authors:  Ihor Luhach; Djaudat Idiyatullin; Conor C Lynch; Curt Corum; Gary V Martinez; Michael Garwood; Robert J Gillies
Journal:  Magn Reson Med       Date:  2013-10-23       Impact factor: 4.668

Review 6.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

7.  A novel hTERT promoter-driven E1A therapeutic for ovarian cancer.

Authors:  Xiaoming Xie; Jennifer L Hsu; Min-Gew Choi; Weiya Xia; Hirohito Yamaguchi; Chun-Te Chen; Bon Q Trinh; Zhen Lu; Naoto T Ueno; Judith K Wolf; Robert C Bast; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.